
SER Stock Forecast & Price Target
SER Analyst Ratings
Bulls say
Serina Therapeutics is positioned favorably due to the advancement of its pipeline candidates, particularly with SER-252, which is targeting high-value indications in neurological diseases and pain management. The company's unique POZ Platform delivery technology offers significant advantages over traditional polymers, potentially enhancing the efficacy and market acceptance of its drug candidates. Importantly, the clinical success of SER-270 could further contribute to long-term growth and valuation, as current assessments do not factor in its potential, indicating significant upside potential for investors.
Bears say
Serina Therapeutics is facing significant financial challenges, highlighted by a reported net loss of $0.64 per share, which is considerably higher than previously estimated projections. The company is grappling with multiple risks, including delays in advancing its key drug candidate, SER-252, through clinical phases, regulatory approval hurdles, and heightened competition which could dampen market traction. Furthermore, the forecasted full-year net loss for 2025 has escalated to $2.01 per share, reflecting a substantial shift in outlook and indicating potential financial instability ahead.
This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
SER Analyst Forecast & Price Prediction
Start investing in SER
Order type
Buy in
Order amount
Est. shares
0 shares